Loading organizations...
§ Private Profile · Waltham, MA, USA
Ventus Therapeutics is a technology company.
Ventus Therapeutics develops novel small molecule medicines using a proprietary structure-based drug discovery platform. This approach integrates structural immunology and computational tools to target proteins within innate immune pathways, focusing on inflammasome and nucleic acid-sensing signaling. Their capabilities enable the pursuit of biologically validated, yet historically challenging, drug targets, allowing the company to open new therapeutic avenues.
Ventus Therapeutics was founded in 2019, launching in 2020, by Harvard Medical School Professor Hao Wu, Yale University Professor Richard Flavell, and Marcelo Bigal. The company's genesis stemmed from the insight that modulating the innate immune system with small molecule medicines offered a critical opportunity to address diverse human diseases. Founders brought extensive backgrounds in structural biology and immunology, establishing a strong scientific foundation.
As a clinical-stage biopharmaceutical company, Ventus Therapeutics delivers transformative small molecule medicines to patients with autoimmune and inflammatory conditions. Their efforts translate deep scientific understanding of innate immune system modulation into effective therapeutic agents. The company's vision is to address unmet medical needs by advancing novel therapies from their platform to patient benefit.
Ventus Therapeutics has raised $300.0M across 3 funding rounds.
Ventus Therapeutics has raised $300.0M in total across 3 funding rounds.
Ventus Therapeutics has raised $300.0M across 3 funding rounds. Most recently, it raised $140.0M Series C in February 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2022 | $140M Series C | Joshua Resnick, John Cassidy | GV, OrbiMed, Versant Ventures, Alexandria Venture Investments, Andreessen Horowitz, BVF Partners, Casdin Capital, Cormorant Asset Management, Qatar Investment Authority | Announced |
| Apr 1, 2021 | $100M Series B | Joshua Resnick | GV, OrbiMed, Versant Ventures, Alexandria Venture Investments, BVF Partners, Casdin Capital, Cormorant Asset Management | Announced |
| May 1, 2020 | $60M Series A | Versant Ventures | GV, OrbiMed | Announced |
Ventus Therapeutics has raised $300.0M in total across 3 funding rounds.
Ventus Therapeutics's investors include Joshua Resnick, John Cassidy, GV, OrbiMed, Versant Ventures, Alexandria Venture Investments, Andreessen Horowitz, BVF Partners, Casdin Capital, Cormorant Asset Management, Qatar Investment Authority.
Ventus Therapeutics is a clinical-stage biopharmaceutical company specializing in structure-based drug discovery for immunology, inflammation, and neurology disorders.[1][2][3] It develops small-molecule therapeutics using its proprietary ReSOLVE platform, which integrates AI/ML, protein science, structural biology, and biophysics to target previously undruggable innate immune pathways.[1][2][3][5] The company serves patients with autoimmune diseases (e.g., lupus), neurological conditions (e.g., Parkinson's, Alzheimer's), and inflammatory disorders by addressing unmet needs where existing therapies fall short.[2][3] Key programs include VENT-02 (brain-penetrant NLRP3 inhibitor in Phase 2 for Parkinson's) and VENT-03 (first-in-class cGAS inhibitor entering Phase 2 for lupus in 2025), alongside partnerships like VENT-01 with Novo Nordisk.[2][3][5] Founded in 2020, Ventus has shown rapid growth, advancing from target screening to multiple Phase 2 trials and securing $60M in Series A funding.[4][5]
Ventus Therapeutics was founded in 2020 by Versant Ventures in Waltham, Massachusetts (with some early ties noted to Canada), launching with a $60M Series A led by Versant and GV (Google Ventures).[1][4][6] The idea emerged from breakthroughs in structural immunology, targeting innate immune pathways undruggable by traditional methods, inspired by genetics and clinical evidence in autoimmune diseases, inflammation, and oncology.[4] Key scientific co-founders and advisors include experts like Judith Lieberman, MD, PhD, who contributed to protein engineering and innate immunity insights.[4][5] Marcelo Bigal, MD, PhD, serves as President and CEO, bringing drug discovery and commercialization experience.[2][4] Early traction was swift: the first target screen in 2020 yielded three development candidates by 2022 (VENT-01, -02, -03), with Phase 1 initiation for VENT-02 in 2023 and a high-value Novo Nordisk partnership.[2][5]
Ventus stands out in biopharma through its focus on challenging innate immune targets. Key strengths include:
Competitors like Azome Therapeutics trail in similar structure-based approaches, but Ventus's platform yields faster, more robust pipelines.[1]
Ventus rides the wave of AI-driven drug discovery and innate immunity targeting, capitalizing on validated biology from genetics (e.g., IL-1B, interferons) and rising demand for oral small molecules in neurology and autoimmunity.[3][4] Timing aligns with post-2020 advances in structural biology tools, enabling "undruggable" targets like cGAS and NLRP3 amid failures by others.[2] Market forces favor it: aging populations drive neurology needs (Parkinson's, Alzheimer's), while autoimmune diseases like lupus lack sufficient therapies; oncology synergies via immune modulation add upside.[1][4] Ventus influences the ecosystem by validating ReSOLVE for partnerships (e.g., Novo Nordisk) and accelerating Phase 2 readouts, potentially reshaping standards for computational biopharma platforms.[2][5]
Ventus is poised for inflection with Phase 2 data from VENT-02 (Parkinson's) and VENT-03 (lupus) in the next 12-18 months, potentially proving ReSOLVE's edge in high-unmet-need areas.[3][5] Trends like AI-biophysics integration and brain-penetrant therapies will amplify growth, with expansion into oncology and more partnerships likely. Its influence may evolve from nimble innovator to pipeline leader, delivering first-in-class options that redefine innate immunity treatments—echoing its launch as a Versant-backed disruptor now translating structure into patient impact.[2][4][5]